Table 2: Distribution of HBV serological markers among the study participants.
|
|
Era |
Total (%) |
||
|
Pre-vaccine era (%) |
Vaccine era (%) |
|||
|
HBsAg |
Positive |
2(1.3) |
4(2.6) |
6(4.0) |
|
Negative |
71(47.3) |
73(48.7) |
144(96.0) |
|
|
HBsAb |
Positive |
1(0.6) |
1(0.6) |
2(1.2) |
|
Negative |
72(48.0) |
76(50.6) |
148(98.7) |
|
|
HBeAg |
Positive |
0(0.0) |
1(0.6) |
1(0.6) |
|
Negative |
73(48.7) |
76(50.6) |
149(99.3) |
|
|
HBeAb |
Positive |
28(18.7) |
23(15.3) |
51(34.0) |
|
Negative |
45(30.0) |
54(36.0) |
99(67.0) |
|
|
HBcAb |
Positive |
15(10.0) |
9(6.0) |
24(16.0) |
|
Negative |
58(38.7) |
68(45.3) |
126(84.0) |
|
|
Total |
73(48.7) |
77(51.3) |
150(100.0) |
|